EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Molecular Targeting of the BRAF Proto-Oncogene/Mitogen-Activated Protein Kinase (MAPK) Pathway across Cancers

Khine S Shan iD, Tauseef U Rehman, Stan Ivanov, Gelenis Domingo, Luis E Raez iD

International Journal of Molecular Sciences · 2024

DOI: 10.3390/ijms25010624 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Khine S Shan und 4 weiteren Autor:innen. Beteiligte Einrichtung: Memorial Health Care, Division of Hematology and Oncology, Pembroke Pines, FL 33328, USA. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Melanoma, Protein Kinase Inhibitors. Die Arbeit wurde bisher 37-mal zitiert (Crossref) und nennt 126 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The mitogen-activated protein kinase (MAPK) pathway is essential for cellular proliferation, growth, and survival. Constitutive activation of this pathway by BRAF mutations can cause downstream activation of kinases, leading to uncontrolled cellular growth and carcinogenesis. Therefore, inhibition of BRAF and the downstream substrate MEK has been shown to be effective in controlling tumor growth and proliferation. Over the last decade, several BRAF and MEK inhibitors have been investigated, ranging from primarily melanoma to various cancer types with BRAF alterations. This subsequently led to several Food and Drug Administration (FDA) approvals for BRAF/MEK inhibitors for melanoma, non-small cell lung cancer, anaplastic thyroid cancer, colorectal cancer, histiocytosis neoplasms, and finally, tumor-agnostic indications. Here, this comprehensive review will cover the developments of BRAF and MEK inhibitors from melanomas to tumor-agnostic indications, novel drugs, challenges, future directions, and the importance of those drugs in personalized medicine.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsMelanomaProtein Kinase InhibitorsHumansMitogen-Activated Protein Kinase KinasesMitogen-Activated Protein KinasesMolecular Targeted TherapyProto-Oncogene Proteins B-raf

Stichwörter der Autor:innen

BRAFERKMAPKMEKmolecular profilingpersonalized medicinetargeted therapytumor agnostic

Substanzen

BRAF protein, humanMitogen-Activated Protein Kinase KinasesMitogen-Activated Protein KinasesProtein Kinase InhibitorsProto-Oncogene Proteins B-raf

Autor:innen und Institutionen

  • Memorial Health Care, Division of Hematology and Oncology, Pembroke Pines, FL 33328, USA.
  • Memorial Health Care, Thoracic Oncology Program, Pembroke Pines, FL 33328, USA.

ORCID-Profile: Khine S Shan, Luis E Raez

Zitieren

APA

Shan, K. S., Rehman, T. U., Ivanov, S., Domingo, G., & Raez, L. E. (2024). Molecular Targeting of the BRAF Proto-Oncogene/Mitogen-Activated Protein Kinase (MAPK) Pathway across Cancers. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms25010624

Vancouver

Shan KS, Rehman TU, Ivanov S, Domingo G, Raez LE. Molecular Targeting of the BRAF Proto-Oncogene/Mitogen-Activated Protein Kinase (MAPK) Pathway across Cancers. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms25010624

BibTeX
@article{Shan2024,
  author = {Shan, Khine S and Rehman, Tauseef U and Ivanov, Stan and Domingo, Gelenis and Raez, Luis E},
  title = {Molecular Targeting of the BRAF Proto-Oncogene/Mitogen-Activated Protein Kinase (MAPK) Pathway across Cancers},
  journal = {International Journal of Molecular Sciences},
  year = {2024},
  doi = {10.3390/ijms25010624}
}
Kostenlos starten →